Cue Biopharma shares jump premarket on positive urticaria trial results
Cue Biopharma shares rallied ahead of the opening bell after positive results in a trial of a prospective treatment for chronic spontaneous urticaria; premarket, the stock was up 51% to $56.00.
Cue Biopharma shares were 51% higher at $56.00 in premarket trading after positive results in a trial of a prospective treatment for spontaneous urticaria, a disease that causes chronic hives.